Cell and Gene Therapy Growth in the UK

Cell and gene therapies, which involve modifying or engineering cells or genes to treat diseases, hold enormous promise, particularly in addressing genetic disorders and cancers. The UK’s world-class research institutions, combined with robust regulatory frameworks, have created fertile ground for innovation. Oliver emphasises, “The UK Cell and Gene Therapy Catapult has played a critical role in this growth. By accelerating the translation of early-stage research into commercial products, it has fostered investment and encouraged collaborations between key industry players.”

Over the next five years, demand for highly skilled professionals in the sector is expected to soar. Roles such as bioprocessing engineers, regulatory experts, and clinical trial managers will be in high demand. “The sector is evolving rapidly,” explains Oliver. “We’re seeing a surge in the need for quality assurance (QA) specialists, especially as companies ramp up manufacturing. Ensuring compliance with Good Manufacturing Practice (GMP) and regulatory standards will be paramount to maintaining safety and efficacy as these therapies scale.”

As the industry grows, the importance of QA professionals will continue to rise. “Experienced QA professionals will be essential as companies scale up their manufacturing capabilities,” Oliver adds. “The role of QA is to ensure that therapies not only meet safety and quality standards but that they can be produced consistently at a larger scale.”

Data science and bioinformatics experts will also play a pivotal role in the future of the sector, with an increased focus on personalising therapies. The integration of scientific, engineering and digital expertise will create a diverse workforce to meet the evolving demands of the sector. “The blending of disciplines is key,” Oliver points out. “This sector is unique in how it brings together biology, technology and data science to push the boundaries of what’s possible in medicine.”

Collaboration between academia, industry and government will be crucial in overcoming challenges such as scaling up manufacturing and navigating regulatory hurdles. “Public-private partnerships are becoming increasingly important,” says Oliver. “These collaborations will be essential for expanding clinical trials, addressing manufacturing challenges, and ensuring patient access to these groundbreaking therapies.”

Looking ahead, investments in advanced manufacturing technologies, such as automation and bioprocessing, will be necessary to meet the growing global demand for cell and gene therapies. “We’re at a critical juncture,” notes Oliver. “Scaling up manufacturing capacity is going to be one of the biggest challenges in the coming years, but it’s also an opportunity to lead the world in this space.”

Patient access will remain a key focus, with ongoing policy discussions around affordability, reimbursement models, and equitable access to treatments. “The ultimate goal is to ensure that these life-saving therapies are accessible to all patients who need them,” concludes Oliver.

Are you looking for a role in Cell & Gene Therapy? Or does your business need professional contractors or permanent staff in this sector?